





## Original Article

# Epidemiology and outcomes of ventilator-associated events in critically ill children: Evaluation of three different definitions

Dimitra Papakyritsi MD<sup>1</sup>, Elias Iosifidis MD, MSc, PhD<sup>1</sup> , Serafia Kalamitsou MD<sup>2</sup>, Elisavet Chorafa MD<sup>1</sup>, Eleni Volakli MD, PhD<sup>2</sup> , Yolanda Peña-López MD<sup>3</sup> , Maria Sdougka MD<sup>2</sup> and Emmanuel Roilides MD, PhD<sup>1</sup> 

<sup>1</sup>Infectious Diseases Unit, Third Department Pediatrics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, and Hippokraton General Hospital, Thessaloniki, Greece, <sup>2</sup>Pediatric Intensive Care Unit, Hippokraton General Hospital, Thessaloniki, Greece and <sup>3</sup>Pediatric Critical Care Department, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain

### Abstract

**Objective:** Ventilator-associated pneumonia (VAP) is one of the most common healthcare-associated infections in pediatric intensive care units (PICUs), but its definite diagnosis remains controversial. The CDC Ventilator-Associated Event (VAE) module (validated in adults) constitutes a new approach for VAP surveillance.

**Design:** We described epidemiological characteristics of PICU VAE cases, investigated possible risk factors, and evaluated 3 different sets of diagnostic VAE criteria.

**Setting:** This study was conducted in a PICU in a tertiary-care general hospital in northern Greece during 2017–2019.

**Patients:** The study included patients aged 35 days–16 years who received mechanical ventilation.

**Methods:** From medical records, we retrieved epidemiological data, clinical data, and laboratory characteristics as well as ventilator settings for our analysis. We assessed “oxygen deterioration” for the tier 1 CDC VAE module using 3 sets of diagnostic criteria: (1) CDC adult VAE criteria [increase of daily minimum fraction of inspired oxygen (FiO<sub>2</sub>) ≥ 0.2 or positive end expiratory pressure (PEEP) ≥ 3 cmH<sub>2</sub>O for 2 days], (2) the US pediatric VAE criteria [increase of FiO<sub>2</sub> ≥ 0.25 or mean airway pressure (MAP) ≥ 4 cmH<sub>2</sub>O for 2 days], and (3) the European pediatric VAE criteria (increase of FiO<sub>2</sub> ≥ 0.2 or PEEP ≥ 2 cmH<sub>2</sub>O for 1 day or increase of FiO<sub>2</sub> ≥ 0.15 and PEEP ≥ 1 cm H<sub>2</sub>O for 1 day).

**Results:** Among 326 children admitted to the PICU, 301 received mechanical ventilation. The incidence rate according to the CDC adult VAE criteria was 4.7 per 1,000 ventilator days. For the US pediatric VAE criteria the incidence rate was 6 per 1,000 ventilator days. For the European pediatric VAE criteria the incidence rate was 9.7 per 1,000 ventilator days. These results revealed statistically significant correlation of all 3 algorithms with adverse outcomes, including mortality.

**Conclusions:** All VAE algorithms were associated with higher mortality rates. Our findings highlight the need for a unified pediatric VAE definition to improve preventive strategies.

(Received 4 January 2022; accepted 16 March 2022; electronically published 4 May 2022)

Ventilator-associated pneumonia (VAP) is one of the most common healthcare-associated infections in pediatric and adult intensive care units (PICUs and ICUs) and has been associated with substantial increases in length of stay, broad-spectrum antibiotic use, morbidity, mortality, and cost.<sup>1–4</sup> However, a definite diagnosis of VAP remains controversial.

The Centers for Disease Control and Prevention (CDC) algorithm for clinically defined pneumonia in mechanically ventilated patients has been widely accepted and is used for surveillance

purposes in both adult and pediatric patients.<sup>5</sup> Nevertheless, there are significant difficulties when applying these criteria for VAP diagnosis, including the requirement of radiographic evidence of pneumonia as well as the reliance on subjective clinical signs and symptoms. For this reason, in January 2013, the CDC introduced a broader and potentially more objective definition for the diagnosis of ventilator-associated events (VAEs), including VAP.<sup>6</sup> Unfortunately, this module has been mostly validated in adults, with very little study in children.<sup>7</sup> Two more VAE algorithms have been proposed for VAE in critically ill children, one by Cocoros et al,<sup>8</sup> which has recently been adopted by the CDC and is the US pediatric VAE criteria (ie, US Ped VAE)<sup>9</sup> and algorithm proposed by Peña-López et al,<sup>10</sup> the European pediatric criteria (ie, EU Ped VAE).<sup>10</sup>

All of the aforementioned algorithms include 3 definition tiers: ventilator-associated complication (VAC), infection-related VAC (IVAC), and possible or probable VAP. The VAC definition

**Author for correspondence:** Elias Iosifidis, E-mail: [iosifidish@gmail.com](mailto:iosifidish@gmail.com)

**PREVIOUS PRESENTATION.** The results of this study were presented in Dimitra Papakyritsi's dissertation for master's degree program, “Pediatric Infectious Diseases,” at the Medical School of National and Kapodistrian University of Athens, on June 23, 2021, in Thessaloniki, Greece.

**Cite this article:** Papakyritsi D, et al. (2023). Epidemiology and outcomes of ventilator-associated events in critically ill children: Evaluation of three different definitions. *Infection Control & Hospital Epidemiology*, 44: 216–221, <https://doi.org/10.1017/ice.2022.97>



depends on respiratory deterioration, designated by objective mechanical ventilation parameters: fraction of inspired oxygen ( $\text{FiO}_2$ ), positive end-expiratory pressure (PEEP), and mean airway pressure (MAP) parameters of mechanical ventilation. Each algorithm includes different bundles of mechanical ventilation parameters.

We have described the epidemiological and clinical characteristics as well as the outcomes of children on mechanical ventilation in a PICU who met each of the 3 proposed sets of criteria for VAE.

## Methods

### Setting and study design

The study was conducted in a multidisciplinary 8-bed PICU in a tertiary-care general hospital in northern Greece. Both medical and surgical patients, including hematology-oncology as well as liver and kidney transplant patients are admitted here. The average number of patients hospitalized yearly is 100–140, and most of them receive mechanical ventilation.

In this retrospective study, we analyzed a cohort of patients hospitalized in the PICU between January 1, 2017 and December 31, 2019 (36 months). Children aged between 35 days and 16 years were included in the study. All mechanical ventilation courses >48 hours were included. Patients with a tracheostomy at admission, as well as patients with permanent tracheostomy, were included. Patients receiving noninvasive mechanical ventilation and patients aged <35 days and >16 years were excluded. In all eligible patients, CDC adult VAE criteria, US Ped VAE criteria, and EU Ped VAE criteria were applied.

The protocol of the study was approved by the Scientific and Bioethics committee of the Hippokraton General Hospital of Thessaloniki (Directors' Board 21st issue no. 31.08.2016). Because it was a retrospective study, no informed consent was needed.

### Definitions

The duration of mechanical ventilation was defined as the total duration of mechanical ventilation until successful extubation for >24 hours. Reintubation before 24 hours was considered persistence of the same course, and reintubation after 24 hours was considered a subsequent course of mechanical ventilation.

PICU length of stay was calculated from time of admission until time of discharge from the PICU. A readmission was considered a separate PICU stay.

In all 3 definitions, the patient must have a  $\geq 2$ -day baseline period of stability or improvement followed by the criteria, which are different for each definition. According to the CDC VAE algorithm for adults, VAC is defined as increase in daily minimum  $\text{FiO}_2 \geq 20\%$  or increase in daily minimum PEEP  $\geq 3 \text{ cmH}_2\text{O}$ , lasting for  $\geq 2$  days. In contrast, the US Ped VAE module defines VAC as increase in daily minimum  $\text{FiO}_2 \geq 25\%$  or increase in daily minimum MAP  $\geq 4 \text{ cmH}_2\text{O}$ , lasting for  $\geq 2$  days. The EU Ped VAE proposed algorithm defines VAC as increase in  $\text{FiO}_2 \geq 20\%$  or increase in PEEP  $\geq 2 \text{ cmH}_2\text{O}$  lasting for 1 day, or increase in  $\text{FiO}_2 \geq 15\%$  and at the same time as an increase in PEEP  $\geq 1 \text{ cmH}_2\text{O}$  lasting for 1 day.

In a patient who fulfills the VAC definition according to the CDC adult VAE and EU Ped VAE algorithms, if temperature ( $T > 38^\circ\text{C}$  or  $< 36^\circ\text{C}$ ) or WBC ( $< 4,000/\text{mm}^3$  or  $\geq 12,000/\text{mm}^3$ ) variation is noted and antibiotic therapy is instituted for at least 4 days, then IVAC is present. The US pediatric definition

differs concerning this tier. According to Cocoros et al,<sup>11</sup> because most patients had abnormal white blood cell counts and temperatures, the surveillance should focus on “pediatric VAC with antimicrobial use” (ie, pediatric AVAC). When criteria of IVAC or AVAC are met according to any of the 3 definitions, and the patient has purulent respiratory secretions ( $\geq 25$  polymorphonuclear cells and  $\leq 10$  squamous epithelial cells per low-powdered field), or positive cultures (endotracheal aspirate  $\geq 10^5 \text{ CFU/mL}$ , BAL  $\geq 10^4 \text{ CFU/mL}$ ), possible pneumonia (PVAP) is defined. When a patient with IVAC has purulent respiratory secretions and positive culture or alternate confirmatory test (positive pleural fluid culture, histopathology, *Legionella* testing or viral testing), then probable pneumonia criteria are met. All 3 currently available VAE criteria for critically ill children are described in Figure 1.

### Data collection—study outcomes

The following data for all eligible patients were extracted from medical records: sex, age, presence of comorbidities, severity-of-illness index (PRISM III 24 score validated for the study population<sup>12</sup>), type of patient (surgical or medical), administration of inotropes, duration of mechanical ventilation, length of stay (ICU), and ICU mortality.


The main outcomes evaluated were VAE rates, mechanical ventilation days, length of stay (ICU), and mortality, especially in patients with VAE. VAE prevalence and incidence rates for each of the 3 VAE definitions were calculated as follows: Prevalence was calculated as the percentage of ventilated patients with VAE, and the incidence was calculated as (number of VAE per total number of ventilator days)  $\times 1,000$ . A monthly record was conducted as VAE per 1,000 ventilator days.

### Statistical analysis

Nominal variables are presented with absolute and relative frequencies, and continuous variables are presented with median and interquartile range (IQR). The association of patient characteristics between patients with and without VAE for each VAE criteria was evaluated using the  $\chi^2$  test of independence and the Mann-Whitney *U* test. Agreement between the different VAE criteria was evaluated using the  $\kappa$  (kappa) score. Univariate and multiple logistic regression analyses were performed to evaluate the association of CDC adult VAE, US Ped VAE, EU Ped VAE with mortality. Results are presented as odds ratios (ORs) with 95% confidence intervals (CIs). Analyses were conducted using SPSS version 20 software (IBM, Armonk, NY). The level of statistical significance was set to  $\alpha = 0.05$ .

## Results

During the study period, among 319 patients admitted to the PICU, 290 (91%) received mechanical ventilation (total days, 4,787) and 249 received mechanical ventilation for  $\geq 3$  days (total day, 4,736). Among them, 141 (56.6%) were male and 90 (36%) were surgical patients (most often postoperative, CNS trauma, or polytrauma). Specifically, the main reasons for admission and intubation were respiratory failure (22.9%), followed by postoperative recovery (21.8%), coma (11.1%), CNS trauma or polytrauma (10.9%), status epilepticus (10.4%), sepsis or septic shock (8.6%), post cardiac arrest and/or return of spontaneous circulation (5.9%), metabolic disorder (3.8%), other (2.9%), and cardiovascular disease (2.5%). The median age was 46 months.



**Fig. 1.** Currently available ventilator-associated event (VAE) criteria for critically ill children. †Microbiological criteria: (1) positive culture via endotracheal aspirate, bronchoalveolar lavage, lung tissue or protected specimen brush, with (semi) quantitative thresholds; (2) purulent respiratory secretions and positive culture via specimens in criterion 1, but not meeting those thresholds for growth; (3) one of the following: organism identified via pleural fluid, lung histopathology, Legionella diagnostic test, or respiratory secretion positive for viral organism. *Note:* PEEP, positive end expiratory pressure;  $\text{FiO}_2$ , fraction of inspired oxygen; Abn, abnormal; MAP, mean airway pressure; WBC, white blood cell count; T, temperature; ABC, antibiotic course; VAC, ventilator-associated complication; IVAC, infection-related VAC; AVAC, pediatric VAC with antimicrobial use; PVAP, possible or probable VAP.

Moreover, 137 patients (55%) suffered from comorbidities and 107 (43%) required administration of inotropes. The median PRISM III 24 score at admission in PICU was 10 (range, 0–52). The median duration of mechanical ventilation was 11 days, and the median length of stay in the PICU was 14 days. Among patients who received mechanical ventilation for  $\geq 3$  days, 43 patients (17%) died (Table 1).

### Epidemiology of VAE

In total, 50 patients (27 males) fulfilled the criteria of at least 1 of the 3 algorithms (20%) and 199 patients did not have a VAE: 24 patients met the CDC adult VAE criteria, 30 patients met the US Ped VAE criteria, and 48 patients met the EU Ped VAE criteria. Also, 22 patients met the VAE criteria according to all 3 algorithms; 2 patients met only the CDC adult VAE criteria; 3 patients met only the US Ped VAE criteria; and 19 patients met only the EU Ped VAE criteria and neither of the other definitions. The median number of mechanical ventilation days at the time of meeting VAE criteria was 9 days. In 25% of patients, VAE occurred until day 5 of mechanical ventilation and in 75% of patients, VAE occurred until day 17 of mechanical ventilation.

### Various VAE definitions

The incidence of CDC VAE was 5 per 1,000 ventilator days; the incidence of US Ped VAE was 6.2 per 1,000 ventilator days; and the incidence of EU Ped VAE was 10 per 1,000 ventilator days. Children with CDC VAE were admitted to the PICU with higher PRISM III 24 scores; they were mostly medical patients and more often required administration of inotropes. Patients with US Ped VAE had been admitted with higher PRISM III 24 scores, were mostly medical patients, and usually required inotropes. These patients also presented with higher PRISM III 24 scores during admission to PICU and more often required inotropes.

### Degree of agreement among the 3 definitions

Substantial agreement was found between CDC adult VAE criteria and both US Ped VAE criteria ( $\kappa = 0.78$ ) and EU Ped VAE criteria ( $\kappa = 0.62$ ). Substantial agreement ( $\kappa = 0.66$ ) was noted between the US Ped VAE and EU Ped VAE criteria.

Of the 30 patients defined as having US Ped VAE, 3 children did not meet the criteria of the 2 other algorithms, probably due to the inclusion of MAP in this specific definition.

### Mortality among children diagnosed with different VAE definitions

The mortality rate in patients on mechanical ventilation during study period was 17.2% ( $N = 249$ ) (Table 1). Among the 43 children who died, 22 children presented VAE with at least 1 of the 3 definitions (51%) and 15 patients met the criteria of all 3 VAE algorithms. Also, 4 patients met only EU Ped VAE criteria, and 1 patient met only the US Ped VAE criteria. The mortality rate was higher in pediatric patients who met the CDC adult VAE criteria ( $n = 24$ , 62.5%) and the US PED criteria ( $n = 30$ , 63%) than in patients who met the EU Ped VAE definition ( $n = 48$ , 46%). In a subanalysis of 19 patients who met the criteria only for EU Ped VAE and patients without VAE (using all definitions), mortality rates were not significantly different ( $P = .24$ ).

In the multivariate analysis of mortality, diagnoses of VAE using the CDC adult VAE criteria, the US Ped criteria, and the EU Ped criteria were significantly associated with higher mortality, considering PRISM III 24 score, comorbidities, and treatment with inotropes (Table 2).

### Median duration of mechanical ventilation and length of stay

The total median duration of mechanical ventilation was 11 days. In children without VAE, the median duration of mechanical ventilation was 9 days. In children with VAE, these durations were

**Table 1.** Patient Characteristics

Variable	CDC VAE			P Value	US Ped VAE			P Value	EU Ped VAE		
	Total	Yes	No		Yes	No	Yes		No	P Value	
Patients, no.	249	24	225		30	219		48	201		
Age median mo (IQR)	46 (10–108)	21 (8.3–80)	48 (11.5–108)	.110	24.5 (10–108.8)	48 (10–108)	.728	24.5 (9–102.8)	48 (11.5–108)	.180	
Sex, male, no.	141	14	127	.859	17	124	.996	26	115	.702	
PRISM III 24 score, median (IQR)	10 (6–13.5)	14 (8–21.5)	9 (5–13)	.011	14.5 (8–20.5)	9 (5–13)	.001	10.5 (8–19)	9 (5–13)	.002	
Surgical patients, no.	90	4	86	.044	5	85	.018	14	76	.263	
Comorbidities, no.	137	15	122	.438	20	117	.172	31	106	.138	
Inotropes, no.	107	17	90	.004	24	83	<.001	33	74	<.001	
Duration of MV, median d (IQR)	11 (5–22)	27.5 (16–67.3)	9 (5–20.5)	<.001	27.5 (15–63.8)	9 (5–20)	<.001	26 (15–48)	8 (5–18)	<.001	
Length of stay, median d (IQR)	14 (7–27)	28.5 (18.8–78.8)	12 (6–24.5)	<.001	28 (16.5–76.3)	12 (6–24)	<.001	27 (16.5–66)	11(6–21)	<.001	
Mortality, no (%)	43 (17.2)	15 (62.5)	28 (12.4)	<.001	19 (63)	24 (11)	<.001	22 (46)	21 (10.4)	<.001	

Note. CDC, Centers for Disease Control and Prevention; VAE, ventilator-associated event; Ped, Pediatric, EU, European; PRISM III 24 score, Pediatric RISK of Mortality (PRISM) III 24 score, MV, mechanical ventilation.

**Table 2.** Multiple Logistic Regression of Mortality

Variable	CDC VAE		US Ped VAE		EU Ped VAE	
	OR	P Value	OR	P Value	OR	P Value
PRISM III 24 score	1.110	<.001	1.105	.001	1.109	<.001
Inotropes	10.054	<.001	8.178	<.001	8.453	<.001
Comorbidities	3.636	.007	3.380	.011	3.340	.010
VAE	8.752	<.001	6.934	<.001	4.053	.001

Note. CDC, Centers for Disease Control and Prevention; VAE, ventilator-associated event; Ped, pediatric; EU, European; OR, odds ratio; PRISM III 24 score, Pediatric RISK of Mortality (PRISM) III 24 score.

27.5, 27.5 and 26 days for CDC VAE, US Ped VAE, and EU Ped VAE, respectively.

The total median length of PICU stay was 14 days. In patients without VAE, the median PICU length of stay was 12 days. For patients with CDC VAE, US Ped VAE, and EU Ped VAE, the median PICU lengths of stay were 28.5, 28 and 27 days, respectively. In a subanalysis of 19 patients who fulfilled criteria only for EU Ped VAE, duration of mechanical ventilation and length of PICU stay were significantly higher ( $P < .001$ ) than in those without any VAE (using all definitions).

## Discussion

Our study is the first to compare the 3 currently available VAE algorithms applied to pediatric patients. We confirmed that VAEs are associated with adverse outcomes, including prolonged mechanical ventilation, longer intensive care duration, and higher mortality rates. The results of this study suggest that different cutoff values of  $\text{FiO}_2$  and PEEP in children result in major differences in the detection of VAE in the pediatric population. They also support the need to develop more objective pediatric VAE criteria for the early detection and treatment of VAP.

Adult studies have shown that the CDC VAE surveillance definition is (1) objective and based on the numerical criteria, (2) less time-consuming, and (3) a robust predictor of outcomes.<sup>13</sup> It also

permits the identification of other ventilator-associated complications such as pulmonary oedema, atelectasis, and acute respiratory distress syndrome.<sup>14</sup>

Additionally, the definition simplifies the surveillance process and minimizes inconsistency within incidence reporting.<sup>15</sup> Results supported by a few previous studies<sup>16,17</sup> suggest that the CDC adult VAE algorithm can also predict adverse outcomes of mechanical ventilation in children (longer duration of mechanical ventilation, longer duration of hospitalization, mortality) and its use by PICUs should not only focus on VAP surveillance but should also include a wider range of complications. In the CDC adult VAE definition, mortality prediction is greater in children than in adults, as noted in this and previous studies.<sup>9,16,18</sup> This observation, along with the lower rates of VAE found in the pediatric population compared with adults,<sup>18,19</sup> confirms that the application of CDC adult VAE criteria in children selects only the severe cases.<sup>10</sup> Thus, it is prudent to further evaluate whether this definition is applicable and beneficial for children.<sup>16</sup>

Cocoros et al<sup>20</sup> proposed a new definition for VAC that is unique to pediatrics.<sup>21</sup> The first tier of this definition (VAC) has recently been adopted by the CDC.<sup>8</sup> These researchers modified the adult definition and used MAP instead of PEEP as a criterion because MAP more accurately reflects changes in lung compliance (which worsens with VAC, frequently along with worsening oxygenation) than PEEP, which is set by clinicians. In addition, this

definition allows high-frequency ventilation to be included in the surveillance definition, given the frequency of its use in neonatal and pediatric populations, although it is excluded in the adult definition.<sup>6</sup> Preliminary data demonstrate that the incidence rate of this newly adopted pediatric VAE ranged between 1 and 4 per 1,000 ventilator days in the United States. The incidence of US Ped VAE on our study was even higher at 6.2 per 1,000 ventilator days.

However, our PICU is relatively small but with high acuity. The US Ped VAE criteria have retrospectively been associated with increased morbidity and mortality,<sup>22–24</sup> which is reflected in our results as well. Although this VAE definition might be useful for neonates undergoing high-frequency oscillatory ventilation, it may be suboptimal in pediatric patients who use higher tidal volumes and PEEP, which is the standard ventilation method in this population.<sup>25</sup> It seems that the US Ped VAE definition selects the most severe cases,<sup>7</sup> which makes its utility in clinical diagnosis controversial. Therefore, a more sensitive definition should be addressed.

Changes regarding oxygenation seem to be the earliest warning sign of complications associated with intubation, whereas degree of hypoxemia is related to worse outcomes.<sup>26</sup> Considering hypoxemia as a key prognostic factor, Peña-Lopez *et al*<sup>10</sup> have suggested the use of a less restrictive definition of VAE (compared with the CDC definition) in children. Using these different thresholds for changes and duration of changes of FiO<sub>2</sub> and PEEP, the EU Ped VAE definition presented increased sensitivity and greater predictive accuracy regarding clinical outcomes in ventilated critically ill children.<sup>10,25</sup> The advantage of the EU Ped VAE definition is that it has been validated prospectively in children,<sup>10</sup> which highlights the need for more prospective studies of pediatric VAEs. In our study, patients who met only the EU Ped VAE criteria (and not the other VAE definitions) had longer duration of mechanical ventilation and lengths of stay than patients without any VAE (using all definitions). However, further research is needed to clarify whether the less strict EU peds criteria may identify more cases with preventable risk factors.

Our study was designed to identify factors associated with pediatric VAC and was not designed to examine causality. We were not able to distinguish whether children experiencing a VAC had suffered a complication of mechanical ventilation or were just displaying progressive respiratory manifestations of the severe illness that necessitated intubation in the first place. Further research is needed to determine whether the currently reported risk factors (eg, surgical admission, inotrope prescription, red blood cell unit transfusion, spontaneous breath trials, type of sedation-continuous vs intermittent- and type of sedative drugs used, early mobility, positive fluid balance)<sup>25</sup> are strongly associated with pediatric VAE and their adverse outcomes.

This study had several limitations. First, it was retrospective nature, and we analyzed a small number of events, which limited the power to identify potential risk factors. Due to single-center nature of this study, interpretation of its results might not be applicable to other settings due to large variation of patient populations and the huge differences in treatment strategies. Being an observational study with no randomization, selection bias may have led to important but unmeasured differences between the comparison groups.

All VAE algorithms were associated with adverse outcomes, including higher mortality rates. Different cutoff values of FiO<sub>2</sub> and PEEP in children resulted in major differences in pediatric VAE detection. The EU Ped VAE criteria presented the highest

incidence rates, and this algorithm may be used as an indicator for implementation of VAE prevention measures.

A unified pediatric VAE definition of ventilator-associated infections and/or events, that is globally accepted is needed and could be used to drive quality improvement efforts and avert outlier antibiotic usage in PICUs.

Prospective validation of the proposed pediatric VAE definitions, along with the identification of risk factors associated with VAE, is needed to improve the definition of VAE and to tailor it to the cardiac, neonatal, and pediatric critically ill patients. Further research is needed to identify optimal strategies for management and prevention of VAEs and/or infections.

#### Acknowledgments.

**Financial support.** No financial support was provided relevant to this article.

**Conflicts of interest.** All authors report no conflicts of interest relevant to this article.

#### References

1. Aelami MH, Lotfi M, Walter Zingg W. Ventilator-associated pneumonia in neonates, infants and children. *Antimicrob Resist Infect Control* 2014; 3:1–10.
2. Foglia E, Meier MD, Elward A. Ventilator-associated pneumonia in neonatal and pediatric intensive care unit patients. *Clin Microbiol Rev* 2007;20:409–425.
3. Venkatachalam V, Hendley JO, Willson DF. The diagnostic dilemma of ventilator-associated pneumonia in critically ill children. *Pediatr Crit Care Med* 2011;12:286–296.
4. Iosifidis E, Pitsava G, Roilides E. Ventilator-associated pneumonia in neonates and children: a systematic analysis of diagnostic methods and prevention. *Future Microbiol* 2018;13:1431–1446.
5. Iosifidis E, Chochliourou E, Violaki A, *et al*. Evaluation of the new Centers for Disease Control and prevention ventilator-associated event module and criteria in critically ill children in Greece. *Infect Control Hosp Epidemiol* 2016;37:1162–1166.
6. Ventilator-associated event (VAE) protocol. Centers for Disease Control and Prevention website. [www.cdc.gov/nhsn/pdfs/pscManual/10-VAEFINAL.pdf](http://www.cdc.gov/nhsn/pdfs/pscManual/10-VAEFINAL.pdf). Published 2013. Accessed April 18, 2022.
7. Willson D, Hall M, Beardsley A, *et al*. Pediatric ventilator-associated events: analysis of the pediatric ventilator-associated infection data. *Pediatr Crit Care Med* 2018;19:e631–e636.
8. Pediatric ventilator-associated event (PedVAE) for use in neonatal and pediatric locations only. Centers for Disease Control and Prevention website. [www.cdc.gov/nhsn/pdfs/pscmanual/pedvae-current-508.pdf](http://www.cdc.gov/nhsn/pdfs/pscmanual/pedvae-current-508.pdf). Published January 2022. Accessed April 18, 2022.
9. Cocoros NM, Priebe GP, Logan LK, *et al*. A pediatric approach to ventilator-associated events surveillance. *Infect Control Hosp Epidemiol* 2017;38: 327–333.
10. Peña-López Y, Pujol M, Campins M, Lagunes L, Balcells J, Rello J. Assessing prediction accuracy for outcomes of ventilator-associated events and infections in critically ill children: a prospective cohort study. *Clin Microbiol Infect* 2019;25:125.
11. Cocoros NM, Priebe G, Gray JE, *et al*. Factors associated with pediatric ventilator-associated conditions in six US hospitals: a nested case-control study. *Pediatr Crit Care Med* 2017;18:536–545.
12. Volaki E, Sdougka M, Tamiolaki M, Tsonidis C, Reizoglou M, Giala M. Demographic profile and outcome analysis of pediatric intensive care patients. *Hippokratia* 2011;15:316–322.
13. Hayashi Y, Morisawa K, Klompas M, *et al*. Toward improved surveillance: the impact of ventilator-associated complications on length of stay and antibiotic use in patients in intensive care units. *Clin Infect Dis* 2013; 56:471e7.
14. Klompas M. Complications of mechanical ventilation and the CDC's new surveillance paradigm. *N Engl J Med* 2013;368:1472e5.

15. Mohd Ali NA, Jauncey-Cooke J, Bogossian F. Ventilator-associated events in children: a review of literature. *Aust Crit Care* 2019;32: 55–62.
16. Phongjitsiri S, Coss-Bu J, Kennedy C, *et al*. The centers for disease control and prevention's new definitions for complications of mechanical ventilation shift the focus of quality surveillance and predict clinical outcomes in a PICU. *Crit Care Med* 2015;43:2446–2451.
17. Klompas M, Khan Y, Kleinman K, *et al*. CDC Prevention Epicenters Program: multicenter evaluation of a novel surveillance paradigm for complications of mechanical ventilation. *PLoS One* 2011;6:e18062.
18. Magill SS, Li Q, Gross C, Dudeck M, Allen-Bridson K, Edwards JR. Incidence and characteristics of ventilator-associated events reported to the National Healthcare Safety Network in 2014. *Crit Care Med* 2016;44: 2154–2162.
19. Fan Y, Gao F, Wu Y, Zhang J, Zhu M, Xiong L. Does ventilator-associated event surveillance detect ventilator-associated pneumonia in intensive care units? A systematic review and meta-analysis. *Crit Care* 2016;20:338.
20. Cocoros NM, Kleinman K, Priebe GP, *et al*. Ventilator-associated events in neonates and children—a new paradigm. *Crit Care Med* 2016; 44:14–22.
21. Magill SS, Klompas M, Balk R, *et al*. Developing a new, national approach to surveillance for ventilator-associated events. *Crit Care Med* 2013;41: 2467–2475.
22. Cocoros NM, Priebe GP, Logan LK, *et al*. A pediatric approach to ventilator-associated events surveillance. *Infect Control Hosp Epidemiol* 2017;38: 327–333.
23. Cirulis MM, Hamele MT, Stockmann CR, *et al*. Comparison of the new adult ventilator-associated event criteria to the centers for disease control and prevention pediatric ventilator-associated pneumonia definition (PNU2) in a population of pediatric traumatic brain injury patients. *Pediatr Crit Care Med* 2016;17:157–164.
24. Beardsley AL, Nitu ME, Cox EG, *et al*. An evaluation of various ventilator-associated infection criteria in a PICU. *Pediatr Crit Care Med* 2016;17:73–80.
25. Peña-López Y, Ramírez-Estrada S, Serrano-Megías M, Lagunes L, Rello J. Short-acting sedative-analgesic drugs protect against development of ventilator-associated events in children: secondary analysis of the EUVAE study. *Respiratory Care* 2021;66:798–805.
26. Fariás JA, Frutos-Vivar F, Casado Flores J, *et al*. Factors associated with the prognosis of mechanically ventilated infants and children. An international study. *Med Intensiva* 2006;30:425–431.